Mark Knapp, MD
Hematology & Oncology · Columbus, OHNPI 1952359549
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 17.8%. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $287.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$12K
- Gilead$9K
- Pharmacosmos Therapeutics Inc.$7K
- Rigel Pharmaceuticals, Inc.$6K
- Karyopharm Therapeutics Inc.$5K
- Incyte Corporation$5K
- plus $23K from 48 others
Across 123 payments — averaging $1517.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$73K
- F. Hoffmann-la Roche AG$54K
- Pharmacyclics LLC, An Abbvie Company$31K
- E.r. Squibb & Sons, L.L.C.$10K
- EMD Serono, Inc.$8K
- Eisai Inc.$6K
- plus $4K from 3 others
What the payments were for
- Consulting fees$36,07854%
- Speaking & faculty fees$21,92133%
- Travel & lodging$3,6795%
- Food & beverage$5,3948%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,171 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 111 | $1,922,019 |
| PomalystPomalidomide | 34 | $779,267 |
| ImbruvicaIbrutinib | 36 | $569,558 |
| JakafiRuxolitinib Phosphate | 23 | $371,568 |
| BrukinsaZanubrutinib | 25 | $353,361 |
| VenclextaVenetoclax | 20 | $326,729 |
| CalquenceAcalabrutinib Maleate | 14 | $217,260 |
| Lenalidomide | 12 | $185,909 |
| XtandiEnzalutamide | 11 | $137,968 |
| Abiraterone Acetate | 19 | $37,724 |
| EliquisApixaban | 15 | $18,058 |
| Hydroxyurea | 110 | $2,052 |
| Dexamethasone | 65 | $1,296 |
| Acyclovir | 34 | $832 |
| Anastrozole | 33 | $642 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $204 | $1,922,019111 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $250 | $779,26734 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $18 | $569,55836 claims |
| Incyte CorporationJakafi | $4,966 | $371,56823 claims |
| Beigene USA, Inc.Brukinsa | $2,667 | $353,36125 claims |
| AbbVieVenclexta | $93 | $326,72920 claims |
| AstraZenecaCalquence | $151 | $217,26014 claims |
| PfizerEliquis | $101 | $18,05815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Columbus
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Sameh MikhailColumbus$135K
- Erin BertinoColumbus$73K
- Kathleen KerriganColumbus$47K
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.